Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Non-penetrating deep sclerectomy in uveitic glaucoma

Poster Details

First Author: S.Al-Obeidan SAUDI ARABIA

Co Author(s):                  

Abstract Details


To assess the long-term efficacy and safety of non-penetrating glaucoma surgery in controlling intraocular pressure (IOP) in uveitic glaucoma.


A Prospective cohort study. at King Abdulaziz University hospital, King Saud University


The study is based on 33 consecutive eyes of 21 patients with uveitic glaucoma who underwent non-penetrating deep sclerectomy with Mitomycin C (MMC) and implant. All patients received anti-inflammatory medications to control intraocular inflammation before and after surgery. Goniopuncture was done for cases that developed uncontrolled postoperative IOP.


Mean (±SD) follow-up was 33.21(± 19.83), (range 12-120) months. IOP reduced from 37.2 to 14.67 mmHg (p < 0.0001). Complete and qualified success was 24/33 (72.7%) eyes, and 7/33 (21.2%) eyes, respectively, with failure in 2 eyes. The mean number of anti-glaucoma medications reduced from 3.24 preoperatively to 0.41 at the last visit (p< 0.0001). YAG goniopuncture was performed in 12 (36.4%) eyes. Postoperative complications included progression of cataract in nine (27.3%) eyes, transient hypotony in 6 (18.2%) eyes, shallow choroidal effusions in four (12.1%) eyes, and hypotony with persistent maculopathy, hyphema and decompression retinopathy in one (3%) eye each.


Deep sclerectomy is safe and effective in patients with uveitic open angle glaucoma. However laser goniopuncture is frequently needed to improve the outcome.

Financial Disclosure:


Back to Poster listing